Literature DB >> 3691615

Increased urinary excretion of toxic hydrazino metabolites of isoniazid by slow acetylators. Effect of a slow-release preparation of isoniazid.

E Peretti1, G Karlaganis, B H Lauterburg.   

Abstract

To test the hypothesis that slow acetylators, who may have a greater risk of developing isoniazid hepatitis than rapid acetylators, are exposed to more acetylhydrazine and hydrazine, two toxic metabolites of isoniazid, the urinary excretion of hydrazino metabolites of isoniazid was measured following the ingestion of 300 mg isoniazid. Slow acetylators (n = 7) excreted significantly more isoniazid (32.4 vs 9.2% dose), acetylhydrazine (3.1 vs 1.6% dose), and hydrazine (1.0 vs 0.4% dose) in 24 h than rapid acetylators (n = 5), whereas the excretion of acetylisoniazid and diacetylhydrazine was significantly lower. As the acetylation (i.e. detoxification) of acetylhydrazine is inhibited in the presence of high concentrations of isoniazid, a study was also made of the effect of a slow-release preparation that results in lower plasma concentrations of isoniazid on the production of hydrazino metabolites. The ratio of acetylisoniazid to isoniazid in urine was significantly increased in slow acetylators from 0.84 to 1.02 following administration of the slow release preparation, indicating increased acetylation of isoniazid. However, the excretion of diacetylhydrazine relative to the excretion of acetylhydrazine and hydrazine did not change. It is concluded that exposure to toxic metabolites of isoniazid is increased in slow acetylators. Detoxification of the toxic metabolites was not enhanced by a slow-release preparation of isoniazid.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3691615     DOI: 10.1007/bf00637563

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  Pharmacokinetics of isoniazid metabolism in man.

Authors:  G A Ellard; P T Gammon
Journal:  J Pharmacokinet Biopharm       Date:  1976-04

2.  Capillary gas-liquid chromatographic determination of the benzodiazepine triazolam in plasma using a retention gap.

Authors:  G Baktir; J Bircher; H U Fisch; G Karlaganis
Journal:  J Chromatogr       Date:  1985-04-12

3.  A study of the effects of rifampicin on isoniazid metabolism in human volunteer subjects.

Authors:  J A Timbrell; B K Park; S J Harland
Journal:  Hum Toxicol       Date:  1985-05

4.  Factors affecting the metabolism of [14C]acetylhydrazine in rats.

Authors:  J M Wright; J A Timbrell
Journal:  Drug Metab Dispos       Date:  1978 Sep-Oct       Impact factor: 3.922

5.  Monoacetylhydrazine as a metabolite of isoniazid in man.

Authors:  J A Timbrell; J M Wright; T A Baillie
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

6.  Is isoniazid-hepatotoxicity induced by the metabolite, hydrazine?

Authors:  A Noda; K Y Hsu; H Noda; Y Yamamoto; T Kurozumi
Journal:  J UOEH       Date:  1983-06-01

7.  Plasma hydrazine concentrations in man after isoniazid and hydralazine administration.

Authors:  I A Blair; R Mansilla Tinoco; M J Brodie; R A Clare; C T Dollery; J A Timbrell; I A Beever
Journal:  Hum Toxicol       Date:  1985-03

8.  Risk factors for isoniazid (NIH)-induced liver dysfunction.

Authors:  D S Dickinson; W C Bailey; B I Hirschowitz; S J Soong; L Eidus; M M Hodgkin
Journal:  J Clin Gastroenterol       Date:  1981-09       Impact factor: 3.062

9.  Oxidation of hydrazine metabolites formed from isoniazid.

Authors:  B H Lauterburg; C V Smith; E L Todd; J R Mitchell
Journal:  Clin Pharmacol Ther       Date:  1985-11       Impact factor: 6.875

10.  Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans.

Authors:  B H Lauterburg; C V Smith; E L Todd; J R Mitchell
Journal:  J Pharmacol Exp Ther       Date:  1985-12       Impact factor: 4.030

View more
  7 in total

1.  Factors in hydrazine formation from isoniazid by paediatric and adult tuberculosis patients.

Authors:  W L Gent; H I Seifart; D P Parkin; P R Donald; J H Lamprecht
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Deficiency of N-acetyltransferase increases the interactions of isoniazid with endobiotics in mouse liver.

Authors:  Pengcheng Wang; Amina I Shehu; Jie Lu; Rujuta H Joshi; Raman Venkataramanan; Kim S Sugamori; Denis M Grant; Xiao-Bo Zhong; Xiaochao Ma
Journal:  Biochem Pharmacol       Date:  2017-09-06       Impact factor: 5.858

3.  Direct oxidation and covalent binding of isoniazid to rodent liver and human hepatic microsomes: humans are more like mice than rats.

Authors:  Imir G Metushi; Tetsuya Nakagawa; Jack Uetrecht
Journal:  Chem Res Toxicol       Date:  2012-10-16       Impact factor: 3.739

Review 4.  Isoniazid metabolism and hepatotoxicity.

Authors:  Pengcheng Wang; Komal Pradhan; Xiao-Bo Zhong; Xiaochao Ma
Journal:  Acta Pharm Sin B       Date:  2016-08-03       Impact factor: 11.413

5.  Integration of genome-scale metabolic networks into whole-body PBPK models shows phenotype-specific cases of drug-induced metabolic perturbation.

Authors:  Henrik Cordes; Christoph Thiel; Vanessa Baier; Lars M Blank; Lars Kuepfer
Journal:  NPJ Syst Biol Appl       Date:  2018-02-26

6.  Application of modified Michaelis - Menten equations for determination of enzyme inducing and inhibiting drugs.

Authors:  Saganuwan Alhaji Saganuwan
Journal:  BMC Pharmacol Toxicol       Date:  2021-10-11       Impact factor: 2.483

7.  Population Pharmacokinetics and Pharmacodynamics of Isoniazid and its Metabolite Acetylisoniazid in Chinese Population.

Authors:  Bing Chen; Hao-Qiang Shi; Meihua Rose Feng; Xi-Han Wang; Xiao-Mei Cao; Wei-Min Cai
Journal:  Front Pharmacol       Date:  2022-07-19       Impact factor: 5.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.